Multiple Myeloma Market Report by Drugs Types. Disease Types, End User, Countries and Companies Analysis 2026-2034

Multiple Myeloma Market Size and Forecast 2026-2034

Multiple Myeloma Market is expected to reach US$ 36.57 billion by 2034 from US$ 23.33 billion in 2025, with a CAGR of 5.12% from 2026 to 2034. Third-party analyses indicated that the multiple myeloma market had experienced steady growth, driven by increasing disease awareness, advancements in targeted therapies, expanding research activities, and improved access to specialized oncology treatment.

Multiple Myeloma Industry Overview

The multiple myeloma industry had evolved significantly due to advancements in oncology research, targeted therapeutics, and precision medicine approaches. Multiple myeloma, a complex hematological malignancy affecting plasma cells, had increasingly gained attention from healthcare providers, pharmaceutical companies, and research institutions worldwide. Third-party assessments had indicated that the industry had witnessed growing demand for innovative treatment options aimed at improving survival outcomes and quality of life for patients. The development of immunotherapies, monoclonal antibodies, proteasome inhibitors, and CAR-T cell therapies had transformed the treatment landscape, offering more personalized and effective therapeutic approaches. Increased awareness regarding early diagnosis and disease monitoring had further contributed to market expansion across developed and emerging healthcare systems.

The industry had also been shaped by rising investments in clinical research and drug development activities. Pharmaceutical manufacturers had focused extensively on expanding therapeutic pipelines and developing next-generation treatments targeting relapsed and refractory multiple myeloma cases. Collaborative research initiatives between biotechnology firms, academic institutions, and healthcare organizations had accelerated innovation within the market. In addition, regulatory support for orphan drugs and breakthrough therapies had encouraged the introduction of advanced treatment options. Improvements in diagnostic technologies, including molecular testing and biomarker-based assessments, had enhanced disease identification and treatment planning. These advancements had strengthened the overall treatment ecosystem and supported broader adoption of innovative therapies.

Recent Developments in the Industry

• February 2026: The FDA is reviewing iberdomide from Bristol Myers Squibb (BMS), which might make it the first celmod (cereblon E3 ligase modulator) to be sold in the US for relapsed or refractory multiple myeloma. As the business gets ready for the diminishing exclusivity of its popular IMiDs Revlimid and Pomalyst, Iberdomide, one of three late-stage celmods in BMS's pipeline, is an important strategic pillar.
• In February 2026, Gilead Sciences announced a final deal to buy Arcellx for USD 7.8 billion, which includes a cash payment of USD 115 per share and a CVR of USD 5 per share. By extending its pipeline outside virology, the acquisition enhances Gilead's position in cell therapy and next-generation immuno-oncology.
• In January 2026, Johnson & Johnson (J&J) filed a request for approval of the teclistamab–daratumumab combination for multiple myeloma with the European Medicines Agency (EMA). In order to provide deeper and longer-lasting responses, the combination combines daratumumab's proven anti-CD38 activity with teclistamab's bispecific T-cell-engaging mechanism.

Growth Drivers for the Multiple Myeloma Market

High-Income Populations Are Aging Quickly

By 2030, 21% of OECD citizens would be 65 or older, up from 17% in 2020. Even if age-adjusted incidence stabilizes, case counts increase because the risk of multiple myeloma doubles every ten years after age 50. Due to the 40% increased incidence of grade-3 cytokine release syndrome in patients, geriatric guidelines now require frailty assessments prior to CAR-T infusion. Daratumumab-hyaluronidase secured 55% of new anti-CD38 prescriptions in the United States during H2 2025, demonstrating the growing demand for subcutaneous and oral formulations that reduce clinic visits.

Increasing Multiple Myeloma Prevalence

As populations age and diagnostic sensitivity increases, incident instances keep rising. The International Agency for Research on Cancer estimates 210,000 new diagnoses per year by 2030, up from an estimated 176,000 in 2024. The post-war baby-boom generation maintains patient inflows thanks to a median diagnosis age close to 69, and improved imaging technologies identify smoldering illness earlier, extending treatment sequences across more therapy lines. Demand is also influenced by ethnic differences; people of African origin have double the incidence of people of European descent, which has led to specialized screening programs in the United States. Even though per-patient expenses are plateauing, each new patient generates sustainable revenue streams because the median survival now surpasses eight years.

Next-Gen Immunotherapies' Launch Pace

Regulators approved two CAR-T designs and three bispecific T-cell engagers between January 2024 and December 2025, reducing clinic-to-market times to less than nine months. In 2025, community oncologists used off-the-shelf medications like teclistamab to provide subcutaneous injections without leukapheresis equipment, resulting in sales of USD 890 million. If continuing trials prove non-inferiority, supplemental filings to shift these medications into second-line use might siphon USD 2 billion yearly from triplet regimens. As efficacy rates converge, safety indicators like cytokine release syndrome incidence are becoming more important in competitive differentiation.

Challenges in the Multiple Myeloma Market

High Cost of Advanced Therapies and Long-Term Treatment

One of the major challenges in the multiple myeloma market had been the high cost associated with advanced treatment options. Innovative therapies such as CAR-T cell therapy, monoclonal antibodies, and combination regimens had significantly increased treatment expenses for healthcare systems and patients. Since multiple myeloma often required long-term disease management, ongoing treatment costs had created substantial financial burdens. Limited reimbursement coverage in certain regions had also restricted patient access to advanced therapies. In developing healthcare markets, affordability concerns had further impacted adoption rates. Additionally, healthcare providers had faced challenges in balancing treatment accessibility with rising oncology expenditures. These financial barriers had remained a critical concern for broader market penetration and equitable patient access to advanced multiple myeloma treatments.

Complexity of Disease Management and Treatment Resistance

Another major challenge had been the complexity associated with managing multiple myeloma and addressing treatment resistance. Multiple myeloma had remained a highly heterogeneous disease, with patients responding differently to available therapies. Over time, many patients had developed resistance to standard treatments, requiring more advanced and often expensive therapeutic interventions. The need for continuous monitoring and personalized treatment adjustments had increased the complexity of disease management. Additionally, side effects associated with long-term therapies had posed challenges for patient adherence and quality of life. Healthcare providers had also required specialized expertise to manage relapsed and refractory cases effectively. These factors had complicated treatment pathways and created ongoing challenges for healthcare systems and pharmaceutical developers.

United States Multiple Myeloma Market

The United States multiple myeloma market had been characterized by strong adoption of advanced oncology therapies and extensive research activity. The country had witnessed significant investments in hematological cancer treatment and drug development, supporting rapid introduction of innovative therapies. Advanced healthcare infrastructure and high awareness regarding early cancer diagnosis had contributed to widespread adoption of targeted therapies and immunotherapies. Clinical trials and regulatory support for breakthrough treatments had further strengthened market growth. Additionally, the presence of major pharmaceutical and biotechnology companies had accelerated innovation within the sector. Increasing prevalence of blood cancers and growing demand for personalized medicine had supported continued expansion of the market. The United States had also remained a key hub for CAR-T therapy development and precision oncology research, contributing to advancements in multiple myeloma treatment approaches and long-term disease management strategies.

• For example, the American Cancer Society estimates that 36,110 new cases of multiple myeloma will be diagnosed in the US in 2025, with 20,030 males and 16,080 women. An estimated 12,030 people are expected to die, with 6,540 men and 5,490 women. According to estimates, the lifetime risk of multiple myeloma in the United States is less than 1%, or roughly 1 in 108 for men and 1 in 133 for women. However, individual risk may differ depending on certain risk factors. Less than 1% of instances of this kind of cancer occur in those under 35, and it primarily affects older folks. The average age at diagnosis is 69, and most people are at least 65 years old.

United Kingdom Multiple Myeloma Market

The United Kingdom multiple myeloma market had been influenced by increasing focus on cancer research, early diagnosis, and access to advanced treatment options. Healthcare organizations had increasingly emphasized specialized hematology care and adoption of innovative oncology therapies. The country had witnessed growing use of targeted treatments and immunotherapies for managing relapsed and refractory multiple myeloma cases. Public healthcare support and ongoing clinical research collaborations had contributed to market development. In addition, advancements in diagnostic technologies had improved disease identification and treatment planning. The expansion of precision medicine initiatives had further strengthened therapeutic adoption across healthcare facilities. Awareness campaigns related to blood cancers and supportive healthcare policies had also contributed to increased patient access to specialized care. Overall, the market had continued evolving through research-driven innovation and expanding oncology treatment capabilities.

China Multiple Myeloma Market

The China multiple myeloma market had experienced growth due to increasing healthcare investments, expanding oncology infrastructure, and rising awareness regarding hematological cancers. Improvements in cancer diagnosis and treatment accessibility had contributed to higher adoption of advanced therapies. The country had also witnessed increasing participation in clinical research and pharmaceutical development activities related to oncology. Government initiatives supporting healthcare modernization had strengthened access to specialized cancer care services. In addition, growing demand for targeted therapies and biologics had encouraged pharmaceutical companies to expand their presence within the Chinese oncology sector. Rising healthcare expenditure and increasing focus on innovative treatment approaches had further supported market development. Despite regional disparities in healthcare accessibility, the adoption of modern multiple myeloma treatment options had continued to increase, particularly in urban healthcare centers and specialized oncology institutions.

United Arab Emirates Multiple Myeloma Market

The UAE multiple myeloma market had been supported by healthcare infrastructure modernization and increasing focus on specialized oncology services. The country had witnessed rising adoption of advanced diagnostic technologies and targeted cancer therapies across leading healthcare facilities. Government initiatives aimed at strengthening cancer care capabilities had contributed to improved access to hematology treatments. Increasing awareness regarding early cancer detection and personalized medicine had further supported market growth. The UAE had also attracted investments in advanced healthcare technologies and international healthcare collaborations, enhancing oncology treatment standards. Demand for innovative therapies, including biologics and immunotherapies, had continued to rise among healthcare providers. In addition, the expansion of private healthcare facilities and medical tourism activities had contributed to broader adoption of advanced cancer treatment solutions. The market had continued evolving with a focus on improving patient outcomes and expanding specialized oncology care services.

Approved Treatments for Multiple Myeloma

• LYNOZYFIC: Regeneron Pharmaceuticals (linvoseltamab)

Adult patients with relapsed or refractory multiple myeloma who have undergone at least four previous lines of treatment—including proteasome inhibitors, IMiD agents, and anti-CD38 monoclonal antibodies—may be treated with LYNOZYFIC, a bispecific B-cell Maturation Antigen (BCMA)-directed CD3 TCE.

January 2026 Regeneron Corporate Presentation: Four registrational studies—LINKER-MM5 (started), LINKER-MM7, LINKER-MM8, and LINKER-SMM2—are now in progress, and four more trials are anticipated to begin in 2026. Pivotal data also predicted beginning in 2027.

• Sanofi's SARCLISA (isatuximab-irfc)

A CD38 monoclonal antibody called SARCLISA (isatuximab) interacts to a particular epitope on the CD38 receptor on multiple myeloma cells to produce unique anticancer activity. It is intended to function by a variety of methods, such as immunomodulatory activity and programmed tumor cell death (apoptosis).

The company's presentation states that SARCLISA is being tested in a subcutaneous formulation for RRMM and that approval in the US, Europe, and Japan is expected in H1 2026.

Multiple Myeloma Market Segments

Drugs Types

• Chemotherapy
• Protease Inhibitors
• Monoclonal Antibody
• Others

Disease Types

• Active multiple myeloma
• Smoldering multiple myeloma

End User

• Hospitals
• Clinics
• Others

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

1. Brazil
2. Mexico
3. Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis

• Novartis AG
• Abbvie Inc.
• Sanofi
• Johnson and Johnson
• Baxter International Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Ltd
• Bristol-Myers Squibb Company

Report Details: